Glucocorticoids and Inflammation Revisited: The State of the Art
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Glucocorticoids have been used in the treatment of inflammatory and autoimmune diseases and to prevent graft rejection for over 50 years. These hormones exert their effects through cytoplasmic, heat shock protein-bound glucocorticoid receptors that translocate into the nucleus, where they regulate the transcriptional activity of responsive genes by binding to specific promoter DNA sequences (transactivation) or by interacting with transcription factors (transrepression). By interacting with different signaling pathways, newly characterized nuclear receptor coregulators enhance or diminish the actions of glucocorticoids, thus explaining the gene-, cell-, tissue- and context-dependent actions of glucocorticoids. Glucocorticoids modulate genes involved in the priming of the innate immune response, while their actions on the adaptive immune response are to suppress cellular [T helper (Th)1-directed] immunity and promote humoral (Th2-directed) immunity and tolerance. The past decade has produced new insights into the mechanisms of glucocorticoid sensitivity and resistance of inflammatory, autoimmune and allergic diseases. Both the quality and severity of the inflammatory stimulus, as well as the genetics and constitution of the patient, play key roles in the glucocorticoid sensitivity, dependency and resistance of these diseases. Although glucocorticoids increase susceptibility to opportunistic infections, they are also highly beneficial in the presence of serious systemic inflammation, such as that observed in septic shock and acute respiratory distress syndrome, when administered in a sustained fashion throughout the course of the disease. Glucocorticoids produce their cardiovascular, metabolic and antigrowth side effects through molecular mechanisms distinct from those involved in immunomodulation. Fortunately, the first generation of tissue- and immune- versus cardiovascular/metabolic effect-selective glucocorticoids is available for study and further improvement. ‘Designer’ glucocorticoids promise to be a great new advance in the therapy of inflammatory diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hypothalamic–Pituitary–Adrenal Axis and Immune-Mediated Inflammation
Chrousos, G. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322008 · Cited by 2,579
Self-citationAuphan, N., DiDonato, J. A., Rosette, C., Helmberg, A., & Karin, M. (1995) · Science · doi:10.1126/science.270.5234.286 · Cited by 2,390
The coregulator exchange in transcriptional functions of nuclear receptors
Glass, C. K., & Rosenfeld, M. G. (2000) · Genes & Development · doi:10.1101/gad.14.2.121 · Cited by 2,233
Annane, D. (2000) · JAMA · doi:10.1001/jama.283.8.1038 · Cited by 1,000
McKay, L. I., & Cidlowski, J. A. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.4.0375 · Cited by 805
Inflammatory Cytokines in the BAL of Patients With ARDS
Meduri, G. U., Kohler, G., Headley, S., Tolley, E., Stentz, F., & Postlethwaite, A. (1995) · Chest · doi:10.1378/chest.108.5.1303 · Cited by 695
Self-citationGlucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans
Bamberger, C. M., Bamberger, A. M., de Castro, M., & Chrousos, G. P. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117943 · Cited by 642
Self-citationGene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells
Galon, J., Franchimont, D., Hiroi, N., Frey, G., Boettner, A., Ehrhart-Bornstein, M., O’shea, J. J., Chrousos, G. P., & Bornstein, S. R. (2002) · The FASEB Journal · doi:10.1096/fj.01-0245com · Cited by 606
Self-citationGlucocorticoids Attenuate T Cell Receptor Signaling
Van Laethem, F., Baus, E., Smyth, L. A., Andris, F., Bex, F., Urbain, J., Kioussis, D., & Leo, O. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.7.803 · Cited by 118
Hypothalamic-Pituitary-Adrenal Axis Suppression and Inhaled Corticosteroid Therapy
Chrousos, G. P., & Harris, A. G. (1998) · Neuroimmunomodulation · doi:10.1159/000026348 · Cited by 50
Self-citation
Cited by
Stress and disorders of the stress system
Chrousos, G. P. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.106 · Cited by 3,215
Self-citationFranz, S., Rammelt, S., Scharnweber, D., & Simon, J. C. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.05.078 · Cited by 1,391
Fries, E., Hesse, J., Hellhammer, J., & Hellhammer, D. H. (2005) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2005.04.006 · Cited by 1,204
“An important role of glucocorticoids during stress is to suppress the production and activity of proinflammatory cytokines, thus restraining the inflammatory reaction and preventing tissue destruction (see McEwen et al., 1997; Ruzek et al., 1999; Franchimont et al., 2003).”
BackgroundGuidelines for the management of inflammatory bowel disease in adults
Carter, M. J., Lobo, A. J., & Travis, S. P. L. (2004) · Gut · doi:10.1136/gut.2004.043372 · Cited by 1,083
Hydrocortisone Infusion for Severe Community-acquired Pneumonia: A Preliminary Randomized Study
Confalonieri, M., Urbino, R., Potena, A., Piattella, M., Parigi, P., Puccio, G., Della Porta, R., Giorgio, C., Blasi, F., Umberger, R., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200406-808oc · Cited by 857
Self-citation
Metadata
- Authors
- Franchimont, D., Kino, T., Galon, J., Meduri, G. U., & Chrousos, G.
- Venue
- Neuroimmunomodulation
- Publisher
- S. Karger AG
- Published
- 2002
- Volume
- 10
- Issue
- 5
- Pages
- 247-260
- ISSN
- 1021-7401 (ISSN-L)
- 1423-0216
- OpenAlex
- W2020121765
- Cited by
- 132
- References
- 10
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucocorticoids and Inflammation Revisited: The State of the Art. https://app.cochat.ai/papers/10.1159/000069969
- The paper
- Franchimont, D., Kino, T., Galon, J., Meduri, G. U., & Chrousos, G. (2002). Glucocorticoids and Inflammation Revisited: The State of the Art. Neuroimmunomodulation. https://doi.org/10.1159/000069969
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.